News about "Phase 3 clinical trial"

Eli Lilly Reports Phase 3 Results for Retatrutide Against Ozempic in Type 2 Diabetes

Eli Lilly has reported positive Phase 3 results for investigational retatrutide, which demonstrated greater reductions in A1C and body weight than Ozempic 2 mg in adults with type 2 diabetes. Retatrutide is not approved for human use.

Phase 3 Clinical Trial | 29/10/2026 | By News Bureau

Suven Completes Phase 3 Enrollment of Masupirdine for Alzheimer's-Related Agitation

Suven Life Sciences completes enrollment in its global Phase 3 masupirdine trial, with 424 patients randomised to evaluate the therapy for agitation associated with Alzheimer’s dementia.

Phase 3 Clinical Trial | 05/09/2026 | By News Bureau |  120

Pharming Launches Joenja in Japan for APDS Patients Aged 4 and Older

Pharming has launched Joenja in Japan for APDS patients aged 4 years and older, making Japan the first market to offer the treatment commercially to children aged 4–11.

Phase 3 Clinical Trial | 14/08/2026 | By News Bureau |  136

Sobi and Innate Pharma Partner to Advance Lacutamab in T-Cell Lymphoma

Sobi and Innate Pharma partners to advance lacutamab into the TELLOMAK-3 Phase 3 trial, supporting its potential accelerated approval in Sézary syndrome and future development across cutaneous T-cell lymphoma.

Phase 3 Clinical Trial | 10/08/2026 | By News Bureau |  150

Gilead and Merck Report Positive Phase 3 Results for Investigational Once-Weekly Oral HIV Therapy

ISLEND-1 and ISLEND-2 trials demonstrate non-inferior efficacy and favourable safety profile, supporting regulatory submissions for what could become the first once-weekly oral HIV treatment.

Phase 3 Clinical Trial | 22/07/2026 | By News Bureau |  218

Opus Genetics Aligns with US FDA on Phase 3 OPGx-LCA5 Trial

Opus Genetics has aligned with the US Food and Drug Administration (FDA) on the Phase 3 trial design for OPGx-LCA5 in inherited retinal disease, with phase 3 dosing expected in Q4 2026 and a potential Biologics License Application (BLA) submission based on 6-month efficacy data.

Phase 3 Clinical Trial | 07/07/2026 | By News Bureau |  231

Glenmark Advances Global Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer

Glenmark Specialty has initiated patient enrolment in India for the Phase 3 trial of trastuzumab rezetecan, aiming to expand treatment options for patients with platinum-resistant ovarian cancer across its licensed global markets.

Phase 3 Clinical Trial | 04/07/2026 | By News Bureau |  200

Newron Provides Update Following Type A Meeting with the US FDA

Newron has provided an update following its Type A meeting with the US Food and Drug Administration (FDA), outlining the steps required to resume US enrollment in the phase 3 ENIGMA-TRS 2 schizophrenia study.

Phase 3 Clinical Trial | 04/07/2026 | By News Bureau |  231

Roche's Divarasib Outperforms KRAS G12C Inhibitors in Phase 3 NSCLC Trial

Roche’s divarasib demonstrated superior Progression-Free Survival over approved KRAS G12C inhibitors in the phase 3 Krascendo-1 trial for previously treated advanced Non-Small Cell Lung Cancer (NSCLC).

Phase 3 Clinical Trial | 02/07/2026 | By News Bureau |  205

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 3 ATLAS-UC Induction

Merck’s tulisokibart achieved both primary and key secondary endpoints in the phase 3 ATLAS-UC induction study, demonstrating significant efficacy in patients with moderately to severely active Ulcerative Colitis (UC).

Phase 3 Clinical Trial | 23/06/2026 | By News Bureau |  507